Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50


Symptom Severity and Quality of Life Among Long-term Colorectal Cancer Survivors Compared With Matched Control Subjects: A Population-Based Study.

Hart TL, Charles ST, Gunaratne M, Baxter NN, Cotterchio M, Cohen Z, Gallinger S.

Dis Colon Rectum. 2018 Mar;61(3):355-363. doi: 10.1097/DCR.0000000000000972.


SCORE: Shared care of Colorectal cancer survivors: protocol for a randomised controlled trial.

Jefford M, Emery J, Grunfeld E, Martin A, Rodger P, Murray AM, De Abreu Lourenco R, Heriot A, Phipps-Nelson J, Guccione L, King D, Lisy K, Tebbutt N, Burgess A, Faragher I, Woods R, Schofield P.

Trials. 2017 Oct 30;18(1):506. doi: 10.1186/s13063-017-2245-4.


RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources.

Wu B, Yao Y, Zhang K, Ma X.

Oncotarget. 2017 Apr 11;8(41):71164-71172. doi: 10.18632/oncotarget.17029. eCollection 2017 Sep 19.


Systematic review of health state utility values for economic evaluation of colorectal cancer.

Jeong K, Cairns J.

Health Econ Rev. 2016 Dec;6(1):36. doi: 10.1186/s13561-016-0115-5. Epub 2016 Aug 19. Review.


Inhibition of emotional needs and emotional wellbeing predict disease progression of chronic hepatitis C patients: an 8-year prospective study.

Sawamoto R, Nagano J, Kajiwara E, Sonoda J, Hiramoto T, Sudo N.

Biopsychosoc Med. 2016 Jul 29;10:24. doi: 10.1186/s13030-016-0075-3. eCollection 2016.


Economic evaluation study (CHEER-compliant): Cost-effectiveness analysis of RAS screening for treatment of metastatic colorectal cancer based on the CALGB 80405 trial.

Zhou J, Zhao R, Wen F, Zhang P, Tang R, Chen H, Zhang J, Li Q.

Medicine (Baltimore). 2016 Jul;95(27):e3762. doi: 10.1097/MD.0000000000003762.


A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer.

Jefford M, Gough K, Drosdowsky A, Russell L, Aranda S, Butow P, Phipps-Nelson J, Young J, Krishnasamy M, Ugalde A, King D, Strickland A, Franco M, Blum R, Johnson C, Ganju V, Shapiro J, Chong G, Charlton J, Haydon A, Schofield P.

Oncologist. 2016 Aug;21(8):1014-23. doi: 10.1634/theoncologist.2015-0533. Epub 2016 Jun 15.


Candidate Predictors of Health-Related Quality of Life of Colorectal Cancer Survivors: A Systematic Review.

Bours MJ, van der Linden BW, Winkels RM, van Duijnhoven FJ, Mols F, van Roekel EH, Kampman E, Beijer S, Weijenberg MP.

Oncologist. 2016 Apr;21(4):433-52. doi: 10.1634/theoncologist.2015-0258. Epub 2016 Feb 24.


Bone Marrow Stromal Antigen 2 Is a Novel Plasma Biomarker and Prognosticator for Colorectal Carcinoma: A Secretome-Based Verification Study.

Chiang SF, Kan CY, Hsiao YC, Tang R, Hsieh LL, Chiang JM, Tsai WS, Yeh CY, Hsieh PS, Liang Y, Chen JS, Yu JS.

Dis Markers. 2015;2015:874054. doi: 10.1155/2015/874054. Epub 2015 Oct 1.


Developing Multivariable Normal Tissue Complication Probability Model to Predict the Incidence of Symptomatic Radiation Pneumonitis among Breast Cancer Patients.

Lee TF, Chao PJ, Chang L, Ting HM, Huang YJ.

PLoS One. 2015 Jul 6;10(7):e0131736. doi: 10.1371/journal.pone.0131736. eCollection 2015.


A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients.

Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C.

BMC Cancer. 2015 Apr 25;15:313. doi: 10.1186/s12885-015-1254-5.


First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.

Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF, Flowers CR.

J Clin Oncol. 2015 Apr 1;33(10):1112-8. doi: 10.1200/JCO.2014.58.4904. Epub 2015 Feb 17.


Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.

Wen F, Yao K, Du ZD, He XF, Zhang PF, Tang RL, Li Q.

World J Gastroenterol. 2014 Dec 21;20(47):17976-84. doi: 10.3748/wjg.v20.i47.17976.


The use of complementary and alternative medicine after the completion of hospital treatment for colorectal cancer: findings from a questionnaire study in Denmark.

Nissen N, Lunde A, Pedersen CG, Johannessen H.

BMC Complement Altern Med. 2014 Oct 10;14:388. doi: 10.1186/1472-6882-14-388.


Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.

Soon SS, Chia WK, Chan ML, Ho GF, Jian X, Deng YH, Tan CS, Sharma A, Segelov E, Mehta S, Ali R, Toh HC, Wee HL.

PLoS One. 2014 Sep 24;9(9):e107866. doi: 10.1371/journal.pone.0107866. eCollection 2014.


LASSO NTCP predictors for the incidence of xerostomia in patients with head and neck squamous cell carcinoma and nasopharyngeal carcinoma.

Lee TF, Liou MH, Huang YJ, Chao PJ, Ting HM, Lee HY, Fang FM.

Sci Rep. 2014 Aug 28;4:6217. doi: 10.1038/srep06217.


Health-related quality of life as a prognostic factor in patients with advanced cancer.

Steel JL, Geller DA, Robinson TL, Savkova AY, Brower DS, Marsh JW, Tsung A.

Cancer. 2014 Dec 1;120(23):3717-21. doi: 10.1002/cncr.28902. Epub 2014 Aug 7.


Cost-effectiveness of first-line treatments for patients with KRAS wild-type metastatic colorectal cancer.

Ewara EM, Zaric GS, Welch S, Sarma S.

Curr Oncol. 2014 Aug;21(4):e541-50. doi: 10.3747/co.21.1837.


Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer.

Shankaran V, Mummy D, Koepl L, Bansal A, Mirick DK, Yu E, Morlock R, Ogale S, Ramsey SD.

Oncologist. 2014 Aug;19(8):892-9. doi: 10.1634/theoncologist.2013-0209. Epub 2014 Aug 1.

Supplemental Content

Support Center